Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167763 | 0.84 | KDM4E (0.35) | ALDH1A1KDM4ELMNAMAPTHTT | |
| SCHEMBL3667600 | 0.79 | HTT (0.32) | HTTCYP3A4 | |
| SCHEMBL24815913 | 0.76 | TNF (0.33) | HTT | |
| SCHEMBL29777989 | 0.76 | ELANE (0.44) | ALDH1A1KDM4E | |
| SCHEMBL1997280 | 0.76 | ELANE (0.44) | ALDH1A1KDM4E | |
| SCHEMBL27248807 | 0.76 | PDE3B (0.40) | ALDH1A1KDM4EMAPTPDE3BPDE3A | |
| SCHEMBL27248775 | 0.72 | TSHR (0.39) | ALDH1A1KDM4EMAPT | |
| SCHEMBL27248956 | 0.71 | PDE3B (0.42) | ALDH1A1KDM4EMAPTPDE3BPDE3A | |
| SCHEMBL27474349 | 0.69 | KDM4E (0.33) | KDM4EMAPTPDE3BPDE3ACYP3A4 | |
| SCHEMBL27248563 | 0.68 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPTPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | ALDH1A1 1422/4885KDM4E 2325/4885LMNA 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.